JNJ-63682918 / J&J, Bavarian Nordic - LARVOL DELTA

Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix (clinicaltrials.gov) - P1/2; N=9; Terminated; Sponsor: Janssen Vaccines & Prevention B.V.; Trial completion date: Dec 2022 ➔ Oct 2020; Active, not recruiting ➔ Terminated; Low enrolment and increasing COVID restrictions, following an earlier enrolment pause in April made it clear that completion of the study would not be feasible

Clinical • Trial completion date • Trial termination • Infectious Disease • Oncology • IFNG • TNFA

Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix (clinicaltrials.gov) - P1/2; N=10; Active, not recruiting; Sponsor: Janssen Vaccines & Prevention B.V.; Recruiting ➔ Active, not recruiting; N=66 ➔ 10

Clinical • Enrollment change • Enrollment closed • Infectious Disease • Oncology • IFNG